Connection
Dara Aisner to Combined Modality Therapy
This is a "connection" page, showing publications Dara Aisner has written about Combined Modality Therapy.
|
|
Connection Strength |
|
|
|
|
|
0.194 |
|
|
|
-
Siegele BJ, Shilo K, Chao BH, Carbone DP, Zhao W, Ioffe O, Franklin WA, Edelman MJ, Aisner DL. Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature. Lung Cancer. 2016 May; 95:65-72.
Score: 0.110
-
Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018 10 15; 24(20):4949-4959.
Score: 0.032
-
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 04; 15(4):504-535.
Score: 0.030
-
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|